. trics. Vancouver, B.C. Clinically, a girl aged 6 months with hepatomegaly, fasting hypoglycaemia and lactic acidosis closely resembled 5 p e 1 glycogenosis (GSD I). However, hepatic biopsy revealed normal glycogen pathway enzymes. Further assays revealed complete absence of Fructose 1:6 diphosphatase (FDPase), but atypically she had shown no glycaemic response to oral galactose and an insignificant response following glucagon injection. A bleeding diathesis was present and abnormal platelet function with reduced platelet adenine nucleotide levels was demonstrated. The 7 children previously reported with absent hepatic FDPase were reviewed; also 8 of their siblings who had similar physical or biochemical abnormalities but died prior to positive diagnosis. There is a high morbidity and mortality during prolonged biochemical diagnostic studies and a marked individual variation in response. Liver biopsy provides optimal definitive diagnosis in spite of the platelet defect described and high overall incidence of abnormal bleed ing in the group as a whole (43%). Adminiatration of glucose 0.5 mg/kg 6 hour by continuous nasogastric infusion corrected the coagulation defect and improved clinical and biochemical parameters, but when the same dose of glucose was given as 3 hourly oral supplements significant hypoglycaemia and bleeding reoccurred intermitently. Many cases described of "atypical GSD I" may represent undiagnosed FDPase deficiency. With attention to the coagulation defect, prompt diagnosis and treatment, prognosis is excellent. Blood glucose concentrations may change from physiologic to pathologic levels and vice versa within a few minutes. This is particularly true of insulin deficient diabetes and therefore the evaluation of glycemic control in children with diabetes is difficult. A less volatile indicator of hyperglycemia is the fraction of hemoglobin A (HbA) that is glycosylated (HbA1). HbAl was determined chromatographically in 30 children with diabetes (13.9 f 2.1%) and 10 non-diabetics (6.8 f 1.4%).
Blood glucose concentrations may change from physiologic to pathologic levels and vice versa within a few minutes. This is particularly true of insulin deficient diabetes and therefore the evaluation of glycemic control in children with diabetes is difficult. A less volatile indicator of hyperglycemia is the fraction of hemoglobin A (HbA) that is glycosylated (HbA1). HbAl was determined chromatographically in 30 children with diabetes (13.9 f 2.1%) and 10 non-diabetics (6.8 f 1.4%).
Incubation of washed red cells from diabetic patients in Krebs bicarbonate buffer with 5mM glucose for 3 hrs. results in no change in the % of HbA1. Sorbitol, a polyol of glucose, accumulates in red blood cells (RBC) in concentrations that corrolate directly with the blood glucose concentration (r=.84). RBC aorbitol concentration in 30 ambulatory diabetics was 33nM/ccPRBC t 13.7 while 10 nondiabetics had sorbitol levels of 5.3 t 2.1.
Incubation of nondiabetic RBC's in 50mM glucose produced an hourly linear increase in sorbitol concentration throughout the 3 hr. incubation reaching diabetic levels in one hour. Reduction of the glucose concentration to 5mM resulted in decreasing but still elevated sorbitol concentrations at one hour with a return to non-diabetic levels by 3 hours.
Thus RBC sorbitol concentration may be a more useful indicator of glycemic control in diabetes than either the blood glucose or HbA1. Glycogen storage disease type I (Von Glerke's disease) Is an autosomal recessive disorder characterized by growth retardation hepatomegaly, recurrent episodes of hypoglycemia and acidosis. The enzyme deficiency in this disease has been shown to be glucose 6-phosphatase, which its activity has been reported mainly in liver and kidneys. In order to find a tissue that may exhibit glucose-6-phosphatase activity, full term human placentas were utilized. Placental slices were washed X3 with cold 0.15 NaCI, then sonicated in 0.1M cacodylate buffer pH 6.5 and centrifuged for 10 min at 10.000 Xg. The supernatant fractions were assayed for glucose 6-phosphatase with glucose 6-phophate. The liberated glucose was determined by glucose oxidase. Normal human term placentas hydrolyze 33.0-80.0 ug glucose/mg/protein/h. 0-1-14~-glucose-6-phosphate was used as an additional substrate and 14~-glucose was identified by thin layer chromatography. Extracts of normal term human placentas release 5 W -8 6 2 of the label/mg protein/h. A regnsncy at risk for glycogen storage disease type I was foleowed and the full term placenta was assayed for glucose 6-phosphatase. The values obtained from the extracts of the placenta at risk released 16.5 ug glucose/nig protein/h. while a n o m l control placenta released 34.0 ug glucose/mg protein/h. This finding suggests heterozygous state of the newborn. These data offer a new source for the study of glucose-6-phosphatase and for possible prenatal detection.
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